Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL

Active:	Yes
Cancer Type:	Leukemia Multiple Myeloma	NCT ID:	NCT05153330
Trial Phases:	Phase I	Protocol IDs:	COVALENT-101 (primary) NCI-2021-14401 BF-MNN-101
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Biomea Fusion Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT05153330

Summary

A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral
covalent menin inhibitor, in adult patients with AML, ALL (with KMT2A/ MLL1r, NPM1
mutations), DLBCL, MM, and CLL/SLL.

Objectives

A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral
covalent menin inhibitor, in adult patients with acute myeloid leukemia (AML), acute
lymphocytic leukemia (ALL) with mixed lineage leukemia 1-rearranged (KMT2A/ MLL1r),
nucleophosmin 1 (NPM1), diffuse large b-cell lymphoma (DLBCL), multiple myeloma (MM), and
chronic lymphocytic lymphoma (CLL)/ small lymphocytic lymphoma (SLL).

Treatment Sites in Georgia

Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)
1000 Johnson Ferry Road NE
Atlanta, GA 30342
404-851-8523

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.